{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:10:09Z","timestamp":1778526609625,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00408-019-00310-8","type":"journal-article","created":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T16:02:52Z","timestamp":1577894572000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis"],"prefix":"10.1007","volume":"198","author":[{"given":"Richard P.","family":"Ramonell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5102-5193","authenticated-orcid":false,"given":"Imran H.","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"310_CR1","unstructured":"https:\/\/ginasthma.org\/severeasthma\/. Accessed 4 Aug. April 2019 edition"},{"key":"310_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr TF, Zeki AA, Kraft M (2018) Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med 197:22\u201337","journal-title":"Am J Respir Crit Care Med"},{"key":"310_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00408-018-0151-5","volume":"196","author":"IH Iftikhar","year":"2018","unstructured":"Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D (2018) Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung 196:517\u2013530","journal-title":"Lung"},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.intimp.2018.08.031","volume":"64","author":"LL He","year":"2018","unstructured":"He LL, Zhang L, Jiang L, Xu F, Fei DS (2018) Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. Int Immunopharmacol 64:223\u2013231","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"310_CR5","doi-asserted-by":"publisher","first-page":"190-200.e20","DOI":"10.1016\/j.jaci.2018.08.031","volume":"143","author":"William Busse","year":"2019","unstructured":"Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB (2019) Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol 143:190\u2013200.e120","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"310_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/cea.12853","volume":"47","author":"Y Cabon","year":"2017","unstructured":"Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A (2017) Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy 47:129\u2013138","journal-title":"Clin Exp Allergy"},{"key":"310_CR7","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128\u20132141","journal-title":"Lancet"},{"key":"310_CR8","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448\u20132458","journal-title":"N Engl J Med"},{"key":"310_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","volume":"33","author":"RM Nowak","year":"2015","unstructured":"Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA (2015) A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 33:14\u201320","journal-title":"Am J Emerg Med"},{"key":"310_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486\u20132496","journal-title":"N Engl J Med"},{"key":"310_CR11","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475\u20132485","journal-title":"N Engl J Med"},{"key":"310_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31\u201344","journal-title":"Lancet"},{"key":"310_CR13","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455\u20132466","journal-title":"N Engl J Med"},{"key":"310_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O\u2019Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355\u2013366","journal-title":"Lancet Respir Med"},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390\u2013400","journal-title":"Lancet Respir Med"},{"key":"310_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198\u20131207","journal-title":"N Engl J Med"},{"key":"310_CR17","doi-asserted-by":"crossref","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G (2015) Meta-analysis with R. Chapter 8. Springer, Cham","DOI":"10.1007\/978-3-319-21416-0"},{"key":"310_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R (2017) Tezepelumab in adults with uncontrolled asthma. N Engl J Med 377:936\u2013946","journal-title":"N Engl J Med"},{"issue":"1","key":"310_CR19","first-page":"122-130.e1","volume":"7","author":"Thomas B. Casale","year":"2019","unstructured":"Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M (2019) Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. J Allergy Clin Immunol Pract 7:122\u2013130.e121","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"5","key":"310_CR20","doi-asserted-by":"publisher","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","volume":"52","author":"Arnaud Bourdin","year":"2018","unstructured":"Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X (2018) Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01393-2018","journal-title":"European Respiratory Journal"},{"key":"310_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:879\u2013890","journal-title":"Lancet Respir Med"},{"issue":"3","key":"310_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/aje\/kwr156","volume":"174","author":"K. J. Rothman","year":"2011","unstructured":"Rothman KJ, Wise LA, Hatch EE (2011) Should graphs of risk or rate ratios be plotted on a log scale? Am J Epidemiol 174:376\u2013377; discussion 377","journal-title":"American Journal of Epidemiology"},{"key":"310_CR23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jclinepi.2009.12.016","volume":"63","author":"MA Levine","year":"2010","unstructured":"Levine MA, El-Nahas AI, Asa B (2010) Relative risk and odds ratio data are still portrayed with inappropriate scales in the medical literature. J Clin Epidemiol 63:1045\u20131047","journal-title":"J Clin Epidemiol"},{"key":"310_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","volume":"59","author":"JG Ayres","year":"2004","unstructured":"Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59:701\u2013708","journal-title":"Allergy"},{"key":"310_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","volume":"59","author":"AM Vignola","year":"2004","unstructured":"Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709\u2013717","journal-title":"Allergy"},{"key":"310_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","volume":"34","author":"ST Holgate","year":"2004","unstructured":"Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J et al (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632\u2013638","journal-title":"Clin Exp Allergy"},{"key":"310_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184\u2013190","journal-title":"J Allergy Clin Immunol"},{"key":"310_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","volume":"60","author":"J Bousquet","year":"2005","unstructured":"Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302\u2013308","journal-title":"Allergy"},{"key":"310_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309\u2013316","journal-title":"Allergy"},{"key":"310_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154:573\u2013582","journal-title":"Ann Intern Med"},{"key":"310_CR31","first-page":"165","volume":"9","author":"D Singh","year":"2017","unstructured":"Singh D, Ravi A, Southworth T (2017) CRTH2 antagonists in asthma: current perspectives. Clin Pharmacol 9:165\u2013173","journal-title":"Clin Pharmacol"},{"issue":"5","key":"310_CR32","doi-asserted-by":"publisher","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","volume":"51","author":"Marc Humbert","year":"2018","unstructured":"Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M, STELLAIR Investigators (2018) Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02523-2017","journal-title":"European Respiratory Journal"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-019-00310-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:17:13Z","timestamp":1609373833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-019-00310-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s00408-019-00310-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}